Frequent Asked Questions
The global Pruritus Treatment Market was valued at USD 8 Billion in 2022.
The Pruritus Treatment Market is expected to grow at a CAGR of 4.80% between 2023 and 2030, reaching USD 11.10756761 Billion in 2030.
Corticosteroids is the leading segment by type, holding over two-thirds share in terms of value in 2022.
The Atopic Dermatitis segment governs the demand for pruritus treatment in the world, holding a massive share of nearly three-fifths in 2022.
The Antihistamines segment is expected to post the highest CAGR during the forecast period.
North America is fuelling the growth of the pruritus treatment industry, with over 42% share in 2022.
The top players include AbbVie Inc., Amgen Inc., Bausch Health Companies Inc., Cara Therapeutics, Inc., Cipla Ltd., Eilly Lilly and Company, Evelo Biosciences, Galderma S.A., LEO Pharma, MC2 therapeutics, Novan, Inc, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi, Trevi therapeutics, Viatris Inc. (Mylan NV).
Increasing prevalence of pruritus worldwide and growing awareness about pruritus among healthcare professionals and patients are the major market drivers.
side effects and safety concerns, and limited treatment options are the major market restraints.
Ongoing advancements in medical research and growing emphasis on patient-centric care in healthcare systems worldwide offer a significant growth opportunity for the Pruritus treatment industry.